PI3K Pathway Inhibitors: Better Not Left Alone
- Auteur
- MARKMAN, Ben1 2 ; TAO, Jessica J3 4 ; SCALTRITI, Maurizio3 4
[1] Monash Medical Centre, Southern Health, Melbourne 3165, Australia
[2] Monash Institute of Medical Research, Monash University, Melbourne 3168, Australia
[3] Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 149, 13th Street, Charlestown, MA, 02129, United States
[4] Harvard Medical School, Boston, MA, United States - Titre de la publication
- Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer
- Auteur (monographie)
- GIOVANNETTI, E (Editor)1 ; PETERS, G. J (Editor)1
[1] Dept. Medical Oncology, VU University Medical Center, Amsterdam, Netherlands - Source
Current pharmaceutical design (Print). 2013, Vol 19, Num 5, pp 895-906, 12 p ; ref : 114 ref
- ISSN
- 1381-6128
- Domaine scientifique
- Pharmacology drugs
- Editeur
- Bentham, Sharjah
- Pays de publication
- United Arab Emirates
- Type de document
- Article
- Langue
- English
- Mot clé auteur
- Akt PI3K inhibitor PI3K PIK3CA PTEN clinical trial mTOR therapeutic combination
- Mot clé (fr)
- 1-Phosphatidylinositol 3-kinase Akt protein kinase Article synthèse Essai clinique Gauche Gène PTEN Gène suppresseur tumeur Homme Inhibiteur Protéine mTOR Traitement Enzyme Transferases
- Mot clé (en)
- 1-Phosphatidylinositol 3-kinase Akt protein kinase Review Clinical trial Left PTEN Gene Tumor suppressor gene Human Inhibitor Mammalian target of rapamycin Treatment Enzyme Transferases
- Mot clé (es)
- 1-Phosphatidylinositol 3-kinase Akt protein kinase Artículo síntesis Ensayo clínico Izquierdo Gen PTEN Gen supresor tumor Hombre Inhibidor Proteína mTOR Tratamiento Enzima Transferases
- Classification
- Pascal
- 002 Sciences biologiques et medicales / 002B Sciences medicales / 002B02 Pharmacologie. Traitements medicamenteux
- Discipline
- General pharmacology
- Provenance
- Inist-CNRS
- Base de données
- PASCAL
- Identifiant INIST
- 27353866
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Accès au Document
Installer sur votre navigateur
DOI
10.2174/138161213804547213 
https://dx.doi.org/10.2174/138161213804547213
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547213\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"895\";s:8:\"\u0000*\u0000epage\";s:3:\"906\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MARKMAN\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Ben\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:14:\"TAO, Jessica J\";i:1;s:19:\"SCALTRITI, Maurizio\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Panist
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547213\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"895\";s:8:\"\u0000*\u0000epage\";s:3:\"906\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MARKMAN\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Ben\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:14:\"TAO, Jessica J\";i:1;s:19:\"SCALTRITI, Maurizio\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Istex
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547213\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Accès par Unpaywall
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547213\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"895\";s:8:\"\u0000*\u0000epage\";s:3:\"906\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MARKMAN\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Ben\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:14:\"TAO, Jessica J\";i:1;s:19:\"SCALTRITI, Maurizio\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Europe PubMed Central
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547213\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"895\";s:8:\"\u0000*\u0000epage\";s:3:\"906\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MARKMAN\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Ben\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:14:\"TAO, Jessica J\";i:1;s:19:\"SCALTRITI, Maurizio\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Base Search
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:26:\"10.2174\/138161213804547213\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:9:\"\u0000*\u0000jtitle\";s:37:\"Current pharmaceutical design (Print)\";s:9:\"\u0000*\u0000stitle\";s:25:\"Curr. pharm. des. (Print)\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:2:\"19\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"895\";s:8:\"\u0000*\u0000epage\";s:3:\"906\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1381-6128\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"MARKMAN\";s:10:\"\u0000*\u0000aufirst\";s:3:\"Ben\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:14:\"TAO, Jessica J\";i:1;s:19:\"SCALTRITI, Maurizio\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:113:\"Development of New Molecular Agents Targeting Key Signalling Pathways Activated by Growth Factors in Human Cancer\";s:8:\"\u0000*\u0000title\";s:46:\"PI3K Pathway Inhibitors: Better Not Left Alone\";s:8:\"\u0000*\u0000place\";s:7:\"Sharjah\";s:6:\"\u0000*\u0000pub\";s:7:\"Bentham\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"12\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par arXiv
